{"id":53958,"date":"2023-02-15T17:05:07","date_gmt":"2023-02-15T16:05:07","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/northstar-medical-radioisotopes-hosting-expansion-event-on-wednesday-february-22-showcasing-advanced-therapeutic-radioisotope-production-technology\/"},"modified":"2023-02-15T17:05:07","modified_gmt":"2023-02-15T16:05:07","slug":"northstar-medical-radioisotopes-hosting-expansion-event-on-wednesday-february-22-showcasing-advanced-therapeutic-radioisotope-production-technology","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/northstar-medical-radioisotopes-hosting-expansion-event-on-wednesday-february-22-showcasing-advanced-therapeutic-radioisotope-production-technology\/","title":{"rendered":"NorthStar Medical Radioisotopes Hosting Expansion Event on Wednesday, February 22, Showcasing Advanced Therapeutic Radioisotope Production Technology"},"content":{"rendered":"
\n

\nFeaturing Remarks by Special Guest Miss America 2023 Grace Stanke, a Wisconsin Native and Nuclear Engineering Student at University of Wisconsin – Madison<\/i>\n<\/p>\n

–(BUSINESS WIRE)–NorthStar Medical Radioisotopes:\n<\/p>\n

<\/a>
<\/a><\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
\n

\nWHAT:<\/b>\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\nNorthStar Medical Radioisotopes will host an event, \u201cCancer Therapy Reimagined – From Belgium to Beloit, Wisconsin\u201d<\/i><\/b> highlighting installation of first-of-its-kind equipment for commercial-scale production of the therapeutic radioisotope actinium-225 (Ac-225) at its facility expansion in Beloit, on Wednesday, February 22, 2023. A customized, 24-ton electron beam accelerator will be hoisted by crane and installed into NorthStar\u2019s new Ac-225 Production facility which will be used exclusively to produce non-carrier added (n.c.a.) Ac-225. The installation marks a significant milestone in the program progress. Chief Executive Officer Stephen Merrick and other NorthStar executives will make remarks to note the occasion. Additional remarks will be made by special guest Miss America 2023 Grace Stanke, a Wisconsin native and a Nuclear Engineering student at the University of Wisconsin – Madison.\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\nMedia are invited to attend and photography\/videography is permitted. Interviews with NorthStar management and Grace Stanke are available, as are facility tours. Please inquire at registration.\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nWHO:<\/b>\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\nRemarks by Stephen Merrick, Chief Executive Officer, additional NorthStar executives and Miss America 2023 Grace Stanke\n<\/p>\n<\/td>\n<\/tr>\n

<\/td>\n<\/td>\n<\/td>\n<\/td>\n\u00a0<\/td>\n<\/tr>\n
\n

\nWHERE:<\/b>\u00a0\u00a0\u00a0\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\nNorthStar Medical Radioisotopes Corporate Headquarters\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\n1800 Gateway Boulevard, Beloit, Wisconsin 53511\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nWHEN:<\/b>\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\nWednesday, February 22, 2023. Reporters are invited to attend at 9:00 \u2013 10:30 a.m. for remarks by NorthStar executives and Miss America 2023 Grace Stanke about the accelerator installation and the promise the emerging field of radionuclide therapy holds for patients and their families dealing with cancer. Please plan to arrive at 9:00 a.m. to check in. Mr. Merrick will speak at 9:25 a.m. The accelerator will be lifted at 9:45 a.m. Facility tours begin at 10:00 a.m.\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nWHY:<\/b>\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\nBeloit-based NorthStar is at the forefront of radioisotope production for the United States as the only commercialized U.S. producer of the important medical radioisotope molybdenum-99 (Mo-99). The new state-of-the-art Ac-225 Production facility is part of NorthStar\u2019s expansion plan to ensure scalable, reliable and environmentally preferable production of the important medical radioisotope Ac-225 for treatment of patients with cancer. Therapeutic radiopharmaceuticals are an emerging and target-specific approach for treating many types of cancer. NorthStar is poised to be the first commercial-scale producer of Ac-225, used to deliver therapeutic doses of radiation that destroy cancer cells while sparing healthy tissue in patients with serious disease.\n<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\n\u00a0\n<\/p>\n<\/td>\n<\/tr>\n

\n

\nCONTACT:<\/b>\n<\/p>\n<\/td>\n

<\/td>\n<\/td>\n<\/td>\n\n

\nFor more information or if you are a reporter interested in attending, please contact Priscilla Harlan on behalf of NorthStar Medical Radioisotopes, (781) 799-7917, or pharlan@shiningrockllc.com<\/a>.\n<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

\nMEDIA BACKGROUDER<\/b>\n<\/p>\n

\n\u201cCancer Therapy Reimagined – From Belgium to Beloit, Wisconsin\u201d
\n
<\/b>NorthStar Medical Radioisotopes Event on February 22, 2023<\/b>\n<\/p>\n

\nShowcasing First-of-its-Kind, Commercial-scale Production of Rare and Important Therapeutic Radioisotope Actinium-225 (Ac-225) for Wisconsin and the United States<\/i>\n<\/p>\n

\nFeaturing Remarks by Special Guest Miss America 2023 Grace Stanke, a Wisconsin Native and Nuclear Engineering Student at University of Wisconsin – Madison<\/i>\n<\/p>\n

\nNorthStar Medical Radioisotopes is hosting an event, \u201cCancer Therapy Reimagined – From Belgium to Beloit, Wisconsin,\u201d <\/i><\/b>highlighting the installation of a first-of-its-kind electron beam accelerator for therapeutic radioisotope production at its new, state-of-the-art Ac-225 Production facility expansion in Beloit on Wednesday, February 22, 2023.\n<\/p>\n

\nAc-225 is an important therapeutic radioisotope that is in highly limited supply and for which no commercial-scale production currently exists. NorthStar is poised to be the first commercial-scale producer of Ac-225, used to deliver therapeutic doses of radiation to destroy cancer cells in patients with serious disease, while sparing healthy tissue. Production of Ac-225 at NorthStar\u2019s new facility will advance large-scale availability of non-carrier added (n.c.a.) Ac-225, for use in treating patients with cancer and other serious disease. The installation is a milestone event in construction progress and Stephen Merrick, Chief Executive Officer, additional NorthStar executives and Miss America 2023 Grace Stanke will make remarks to note the occasion.\n<\/p>\n

\nFrom Belgium to Beloit – the electron beam accelerator
\n
<\/i><\/b>A custom-built, 24-ton Rhodotron\u00aeTT 300-HE (High Energy) electron beam accelerator will be hoisted by crane and installed into NorthStar\u2019s new Accelerator Production facility.\n<\/p>\n